MedTrace Logo

Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)

NCT00483730 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 569

Last updated 2012-05-07

No results posted yet for this study

Summary

To assess clinical efficacy and safety of Actovegin in type 2 diabetic patients with symptomatic diabetic peripheral polyneuropathy after 250 ml i.v. infusions once daily for 20 days followed by oral treatment 600 mg × 3 daily for 140 days.

Conditions

  • Symptomatic Diabetic Peripheral Polyneuropathy

Interventions

DRUG

Deproteinised hemoderivative of calf blood (Actovegin)

Symptomatic diabetic peripheral polyneuropathy

Sponsors & Collaborators

  • Nycomed

    lead INDUSTRY

Principal Investigators

  • Nycomced Clinical Trial Operations · Headquaters

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-05-31
Completion
2008-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00483730 on ClinicalTrials.gov